1-2 of 2
Christoph Gaul, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Type II Inhibition of JAK2 with NVP-CHZ868 Reverses Type I JAK Inhibitor Persistence and Demonstrates Increased Efficacy in MPN Models

Sara C Meyer, MD PhD, Matthew D Keller, BS, Priya Koppikar, PhD, Olga A Guryanova, MD PhD, Maria Kleppe, PhD, Anna Sophia McKenney, MPH, William R Sellers, MD, Francesco Hofmann, PhD, Fabienne Baffert, Christoph Gaul, PhD, Thomas Radimerski, PhD, Ross L Levine, MD
Journal: Blood
Blood (2014) 124 (21): 160.
https://doi.org/10.1182/blood.V124.21.160.160
Published: 2014
Journal Articles

Type II JAK2 Inhibitor NVP-CHZ868 Is Active in Vivo Against JAK2-Dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs)

Loretta S. Li, MD, Shuo-Chieh Wu, Nadja Kopp, MA, Joan Montero, PhD, Jeremy Ryan, SM, Bjoern Chapuy, MD PhD, Jordy C. Van der Zwet, Jacob Layer, Oliver Weigert, MD, Amanda L Christie, Alexandra N. Christodoulou, Huiyun Liu, Akinori Yoda, PhD, Francesco Hofmann, PhD, Fabienne Baffert, Eric Vangrevelinghe, Christoph Gaul, PhD, Thomas Radimerski, PhD, Anthony G. Letai, MD PhD, David M. Weinstock, MD
Journal: Blood
Blood (2014) 124 (21): 3713.
https://doi.org/10.1182/blood.V124.21.3713.3713
Published: 2014